Rule 1: Molecules containing a sulfonyl group (SO2R) or a carbonyl group (COR) have the potential to cause adverse effects in relation to skin and subcutaneous tissue disorders.
Rule 2: Molecules that contain a nitro group (NO2) may not cause adverse effects in relation to skin and subcutaneous tissue disorders.
Rule 3: Molecules with a chlorine atom (Cl) bonded to an aromatic ring may not cause adverse skin and subcutaneous tissue effects.
Rule 4: Molecules that contain a sulfonamide group (-SO2NH2) or a sulfonyl group (-SO2R) potentially have side effects related to skin and subcutaneous tissue disorders.
Rule 5: Compounds with a sulfonyl group (SO2R) or a phosphate group (PO4R) may cause side effects on skin and subcutaneous tissues.
Rule 6: Compounds containing iodine atoms potentially have side effects on skin and subcutaneous tissues.
Rule 7: Compounds containing gadolinium ions (Gd3+) potentially have side effects on skin and subcutaneous tissues.
Rule 8: Presence of a carbonyl group (C=O) or carboxylic acid group (COOH) in a compound increases its potential for causing adverse effects on skin and subcutaneous tissues.
Rule 9: A compound with multiple rings or aromatic structures may cause adverse effects on skin and subcutaneous tissues.
Rule 10: Compounds containing halogen atoms such as chlorine or fluorine may cause adverse effects on skin and subcutaneous tissues.
Rule 11: Compounds containing a sulfonamide group (-SO2NH-) or a nitro group (-NO2), may cause side effects on skin and subcutaneous tissues.
Rule 12: Compounds with a fluorine atom attached to a carbon atom in its structure may also cause side effects on skin and subcutaneous tissues.
Rule 13: Compounds with a carbonyl group (-C=O) adjacent to a double bond, may cause side effects on skin and subcutaneous tissues.
Rule 14: Molecules with a sulfonamide group (-SO2NH2) or a nitro group (-NO2) have the potential to cause adverse effects in relation to skin and subcutaneous tissue disorders.
Rule 15: The presence of a sulfonyl group (-SO2-) or sulfate group (-OSO3-) in a molecule may cause skin and subcutaneous tissue disorders.
Rule 16: Molecules with a nitro group or a halogen group such as chlorine (-Cl) or fluorine (-F) attached to an aromatic ring, may cause skin and subcutaneous tissue disorders.
Rule 17: Molecules containing sulfonamide groups or nitro groups can potentially cause skin and subcutaneous tissue disorders.
Rule 18: Molecules containing a sulfonamide group or a nitro group may potentially cause skin and subcutaneous tissue disorders.
Rule 19: Molecules containing a sulfonyl group or a carbonyl group can potentially cause skin and subcutaneous tissue disorders.
Rule 20: The presence of chlorine atoms in a compound may potentially cause skin and subcutaneous tissue disorders.
Rule 21: Compounds containing nitro groups may cause skin sensitization, irritation, and corrosion.
Rule 22: Compounds containing a carbonyl group in the structure may have potential side effects on skin and subcutaneous tissues.
Rule 23: Compounds containing a cyano group in the structure may have potential side effects on skin and subcutaneous tissues.
Rule 24: Sulfonyl group or a sulfate group in a molecule increases its likelihood of causing skin and subcutaneous tissue disorders.
Rule 25: Compounds with nitro or carbonyl groups can cause allergic reactions or irritation to the skin and tissues.
Rule 26: Compounds with halogen atoms like chlorine or bromine in the structure may lead to adverse effects on human health.
Rule 27: Molecules containing a functional group such as nitro or carbonyl groups can cause allergic reactions or irritation to the skin and tissues.
Rule 28: Sulfonamide group in a compound may increase its potential to cause skin and subcutaneous tissue disorders.
Rule 29: Molecules containing a nitro group and halogen atom have a higher chance of causing skin and subcutaneous tissue disorders.
Rule 30: Compounds containing a carbonyl group and a sulfur atom bonded to another non-hydrogen atom, have a high probability of causing skin and subcutaneous tissue disorders.
Rule 1: Compounds that contain a sulfonamide group (-SO2NH-) or a nitro group (-NO2) may potentially have side effects on skin and subcutaneous tissues.

Rule 2: Compounds with a fluorine atom attached to a carbon atom might also have potential side effects on the skin and subcutaneous tissues.

Rule 3: Compounds that have a carbonyl group (-C=O) adjacent to a double bond may also have potential side effects on skin and subcutaneous tissues.

Rule 4: The presence of functional groups such as aldehydes, ketones, carboxylic acids, esters, amides, and amines can lead to irritation or inflammation, increasing the compound's potential to cause adverse effects on skin and subcutaneous tissues.

Rule 5: A compound that contains halogen atoms like chlorine, bromine, or iodine has the potential to cause adverse effects on skin and subcutaneous tissues due to their capability to react with nucleophilic sites on proteins, leading to cell damage or death.

Rule 6: Sulfur-containing compounds and phosphorous-containing compounds may also cause adverse effects on skin and subcutaneous tissues.

Rule 7: If a compound contains a cyano group (-CN), a sulfhydryl group (-SH) attached to a peptide bond, or a fluorine atom adjacent to the carbonyl group, it may cause potential skin and subcutaneous tissue disorders.

Rule 8: The presence of sulfonyl, nitro, or carbonyl groups, aromatic rings or conjugated double bonds, or high molecular weight or complex structures in a compound may increase its potential for causing adverse effects on skin and subcutaneous tissues.

Rule 9: Compounds with nitrogen atoms, especially in the form of heterocyclic rings, may pose a higher risk of adverse reactions.

Rule 10: Gadolinium presence in the structure, chlorine atoms, carbonyl, carboxyl, or nitro groups, may signify the potential for having adverse effects on skin and subcutaneous tissues.

Rule 11: A molecule with a benzene ring attached through a carbonyl group may have potential adverse effects. 

Rule 12: Compounds with molecular weights greater than 500 Daltons might have lower bioavailability and be least likely to cause side effects.
